The short answer
TB-500 research must first identify the molecule. The selected study examines the acetylated fragment Ac-LKKTETQ in laboratory systems and rats, not clinical treatment in dogs.
Identify the substance before reading the claims
The fragment studied as TB-500 and full-length thymosin beta-4 are not interchangeable. Check the sequence and formulation before applying findings from either molecule to a product.
| Study | Species and design | What it measured | Limitations |
|---|---|---|---|
| Rahaman et al., 2024 | Human serum, enzyme systems, rat urine and fibroblast assays | Analysed the parent fragment and metabolites. A wound-closure signal was reported for a metabolite, not the parent, in the cell assay. | Cell migration and rat metabolism are not canine clinical efficacy or safety. Full-length thymosin beta-4 studies cannot stand in for this fragment. |
Source checked 13 October 2026 against the primary bibliographic record and abstract. This is a selected-source summary, not a systematic review or an independent veterinary endorsement. The author and publisher are PET157; no external clinical reviewer is claimed.
What to ask next
Ask your veterinarian about the diagnosis, established care and how the cited species, formulation and outcome relate to the question. Research information is separate from Australian approval, lawful supply and individual clinical suitability. No administration instructions are provided here.